Nanomedicine: Promises and challenges

Basit, Erha; Shamsi, Farwa Batool; Kiyani, Maryam Zaheer; Ramzan, Shmaim; Ahmad, Awais; Khan, Anish

doi:10.1016/b978-0-12-820773-4.00016-0

Cited by 2 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The field of nanomedicine encompasses nanomaterials, biological devices, biosensors, and even novel uses of molecular nanotechnology, such as biological machines. 12 NPs can be employed in three major fields of nanomedicine for clinical applications: diagnostics, controlled medication delivery, and regenerative medicine. 13 Theragnostics, an emerging field that integrates detection and treatment, is a viable technique that holds the identification agent and treatment in the same system.…”

Section: Nanodrugs and Nanomedicinementioning

confidence: 99%

“…The use of NPs in illness detection, tracking, management, and therapy is known as nanomedicine. The field of nanomedicine encompasses nanomaterials, biological devices, biosensors, and even novel uses of molecular nanotechnology, such as biological machines . NPs can be employed in three major fields of nanomedicine for clinical applications: diagnostics, controlled medication delivery, and regenerative medicine …”

Section: Nanodrugs and Nanomedicinementioning

confidence: 99%

See 1 more Smart Citation

Toxicity of Polymeric Nanodrugs as Drug Carriers

Sairam,

Sanmugam,

Pushparaj

et al. 2023

ACS Chem. Health Saf.

View full text Add to dashboard Cite

The ambiguity of certain diseases and the potential toxicity of many medications have sparked demand for the incorporation and enhancement of drug delivery systems (DDSs). Nanomedicine has received renewed attention in modern medical advancements with therapeutic uses. Therefore, the development of nanomedicines for enhanced bioaccessibility, long drug administration, and dose reduction has advanced as a unique concept. Nanocapsules, nanoemulsions, drug nanocrystals, micelles, solid lipid nanoparticles (SLNs), and polymeric nanoparticles (poly-NPs) are among the most effective nanomedicine techniques. Poly-NPs have emerged as a potential method to enhance drug pharmacokinetics. Pharmaceutical potency can be increased by using nanocarriers and medication formulations. The potential of poly-NPs to alter contemporary medicine has attracted significant interest; polymer adaptability makes them suitable for site-specific drug delivery requirements. However, little is known about their safety in long-term studies using high-pitched doses. These cells exhibit some extrapyramidal symptoms (EPS) because of the reactivity and size reduction of the polymers chosen by using living cells other than the target. With an increased understanding of polymers and their properties, it is equally important to emphasize the safety and toxicity of DDSs. Some of the toxic effects of polymeric nanodrugs include an increase in the cytotoxicity of the cell, reduction in the feasibility of the cell, increase in the rate of programmed cell death (apoptosis), precursors for tumor formation, DNA destruction, gene toxicity, rupture of the cell membrane, and lipid peroxidation reactions. In this article, we discuss the toxicity of nanoparticles (NPs) used in DDSs, including polylactide-co-glycolide, polylactic acid, polycaprolactone, and poly(alkyl cyanoacrylates), used in DDSs.

show abstract

Section: Nanodrugs and Nanomedicinementioning

confidence: 99%

Section: Nanodrugs and Nanomedicinementioning

confidence: 99%

Toxicity of Polymeric Nanodrugs as Drug Carriers

Sairam,

Sanmugam,

Pushparaj

et al. 2023

ACS Chem. Health Saf.

View full text Add to dashboard Cite

show abstract

“…Doxil was the first Food and Drug Administration (FDA)‐approved nanomedicine that used liposome technology. Doxil has been shown to have a significantly higher blood circulation time, improved stability, and lower cardiac toxicity compared with free doxorubicin, enabling clinical use at higher doses (Basit et al, 2021). Additionally, protein‐based nanoparticles have the advantage of increased bioavailability (Li, Luo, & Pu, 2021; Li, Ng, et al, 2021).…”

Section: Development Of Antitumor Nanomedicines and Challenges In The...mentioning

confidence: 99%

Organoids technology for advancing the clinical translation of cancer nanomedicine

Zhao

Liang

Huang

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The past decades have witnessed the rapid development and widespread application of nanomedicines in cancer treatment; however, the clinical translation of experimental findings has been low, as evidenced by the low percentage of commercialized nanomedicines. Incomplete understanding of nanomedicine‐tumor interactions and inappropriate evaluation models are two important challenges limiting the clinical translation of cancer nanomedicines. Currently, nanomedicine‐tumor interaction and therapeutic effects are mainly investigated using cell lines or mouse models, which do not recapitulate the complex tumor microenvironment in human patients. Thus, information obtained from cell lines and mouse models cannot provide adequate guidance for the rational redesign of nanomedicine. Compared with other preclinical models, tumor organoids constructed from patient‐derived tumor tissues are superior in retaining the key histopathological, genetic, and phenotypic features of the parent tumor. We speculate that organoid technology would help elucidate nanomedicine‐tumor interaction in the tumor microenvironment and guide the design of nanomedicine, making it a reliable tool to accurately predict drug responses in patients with cancer. This review highlighted the advantages of drug delivery systems in cancer treatment, challenges limiting the clinical translation of antitumor nanomedicines, and potential application of patient‐derived organoids (PDO) in nanomedicine. We propose that combining organoids and nanotechnology would facilitate the development of safe and effective cancer nanomedicines and accelerate their clinical application. This review discussed the potential translational value of integrative research using organoids and cancer nanomedicine.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Nanomedicine: Promises and challenges

Cited by 2 publications

References 56 publications

Toxicity of Polymeric Nanodrugs as Drug Carriers

Toxicity of Polymeric Nanodrugs as Drug Carriers

Organoids technology for advancing the clinical translation of cancer nanomedicine

Contact Info

Product

Resources

About